| abstract |
Diseases that are completely or partially mediated by metabotropic glutamate receptor type 5, such as acute, traumatic and chronic neurodegenerative processes (Alzheimer's disease, senile dementia, Parkinson's disease, Huntington's disease, muscle atrophy) 4- [1-aryl-imidazole-4-] for treatment or prevention of psychosis such as schizophrenia and anxiety; depression; pain; and drug addiction Ileethynyl] -2-alkyl-pyridine and 4- [1-heteroaryl-imidazol-4-ylethynyl] -2-alkyl-pyridine derivatives, and pharmaceutically acceptable salts thereof. |